deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT07083817

Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants

A Single-dose, Phase 1, Open-label Study to Evaluate the Mass Balance and Absorption, Distribution, Metabolism, and Excretion of [14C]Xeruborbactam (QPX7728) Following Administration of a Solution for Intravenous Infusion in Healthy Adult Male Participants

Sponsor: Qpex Biopharma, Inc.

Conditions ADME
Interventions [14C]Xeruborbactam
Updated 2 times since 2025 Last updated: Aug 28, 2025 Started: Aug 13, 2025 Primary completion: Aug 27, 2025 Completion: Aug 27, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on ADME, this trial is completed. The trial is conducted by Qpex Biopharma, Inc. and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshotNot Yet Recruiting~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

2 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE1

    Status: Not Yet RecruitingCompleted

  2. Aug 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Qpex Biopharma, Inc.
  • Shionogi Inc.
Data source: Qpex Biopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations